The FDA approval of pritelivir offers an oral treatment for refractory HSV lesions in immunocompromised adults, with drug interactions creating an important role for pharmacists.
News|Articles|October 12, 2026
Could Cemdisiran Keep Patients With Myasthenia Gravis Out of the Hospital?
In an interview with Pharmacy Times, Ali A. Habib, MD, clinical professor of neurology at the University of California, Irvine, discusses what the hospitalization findings mean for patients and why they should be viewed as supportive evidence
Advertisement
Advertisement
For patients with generalized myasthenia gravis (gMG), treatment success extends beyond a change in symptom scores. Preventing severe disease worsening and limiting the time patients spend in the hospital are important goals, particularly for older adults with other health conditions. Hospitalization findings from the phase 3 NIMBLE trial raise questions about whether cemdisiran, an investigational small interfering RNA (siRNA) therapy targeting complement component 5 (C5) production, could help address that burden.
Related to this article
Weltruza, the first subcutaneous long-acting injectable (LAI) formulation of olanzapine, requires no loading doses, oral supplementation, or postinjection monitoring.
The first AHA endocarditis update in 11 years expands outpatient options, with a bigger role for pharmacists.
Investigational inhaled stem cells for COPD raise questions about lasting clinical benefit and the pharmacy controls needed to deliver a living-cell product through a nebulizer.
A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague, and which antibiotics the CDC recommends.
In an interview with Pharmacy Times, Abdulkader Rahmo, PhD, discusses investigational inhaled cell therapy for COPD, the evidence needed to establish lasting clinical benefit, and pharmacists’ potential role in its delivery.
The gap is not a paperwork inconvenience—it is a cash flow problem with clinical consequences.
In an interview with Pharmacy Times, City of Hope researchers discuss a preclinical platform designed to redirect CAR T cells after infusion and how pharmacists could help bring this adaptable approach into clinical practice.
Advertisement
Advertisement